| Budget Amount *help |
¥26,910,000 (Direct Cost: ¥20,700,000、Indirect Cost: ¥6,210,000)
Fiscal Year 2009: ¥7,410,000 (Direct Cost: ¥5,700,000、Indirect Cost: ¥1,710,000)
Fiscal Year 2008: ¥7,670,000 (Direct Cost: ¥5,900,000、Indirect Cost: ¥1,770,000)
Fiscal Year 2007: ¥11,830,000 (Direct Cost: ¥9,100,000、Indirect Cost: ¥2,730,000)
|
|---|
| Research Abstract |
We reported hypo responsiveness of NKT cells in cancer-bearing state. In animal models, CD11b+ Gr1+ cells are increased in cancer-bearing state, which produce nitric oxide and suppress NKT cell functions. We reported also all trans retinoic acid (ATRA) can absolve hypo responsiveness of NKT cells in cancer-bearing state. We showed clearly in this study that CD11b+ Gr1+ cells in animal models were CD33+ CD14- CD11b+ cells in human, and this population suppressed NKT cell functions in cancer patients. We also indicated that ATRA is able to absolve hypo responsiveness of NKT cells in cancer patients in vitro. CD11b+ Gr1+ cells which increased in cancer patients more expressed VEGF than in healthy donors, but FOXP3 expressions were no significant difference between cancer patient and healthy donors. There was a trend toward that CD33+ CD14- CD11b+ cells were reduced after cancer therapy using with anti VEGF antibody. Based on the result of this study, we indicate that anti VEGF antibody which is already used as cancer therapy drug could be have ability of reducing immune suppression in cancer patient. We believe that this result will be important basic study for new cancer therapy using with NKT cells and we can use this treatment for several cancer therapy commencing with colorectal cancer.
|
